"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors - Wikidata - wikimedia - TriplyDB

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors

http://www.wikidata.org/entity/Q33618910

about

Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy.

P2860

Q47761787-A2B910A4-843E-4BED-A8C0-AFB14EEBFE13

P2860

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors

http://www.wikidata.org/entity/Q33618910

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors

@ast

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors

@en

type

label

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors

@ast

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors

@en

prefLabel

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors

@ast

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors

@en

P1433

Q33618910-0F662670-17F4-47C2-AA13-50140A717A7E

P1476

Q33618910-5D41FE4A-5B20-428C-8864-AB1B045DB68B

P2093

Q33618910-1216C5AA-4F8C-4DD6-8456-098A6F5A0A3B

Q33618910-1E21252E-3BC7-4BAE-BC17-AE502D266500

Q33618910-660C4849-2A05-4AFC-9E23-01932F524091

Q33618910-6B3201E1-373B-43A9-86AC-E4F9FA6DFE78

Q33618910-706AEA94-2358-49F2-9046-21E6DC31D642

Q33618910-7A1FEAC4-5BB7-475D-8B02-1B1F407D6676

Q33618910-A6D1EA47-72E7-448C-AE4F-A576D3921005

Q33618910-D4E48BAA-6CF4-4958-8B29-C302055B1EAB

Q33618910-D5074F53-8D5B-4F29-B7FF-B7A72F80742C

Q33618910-D8546EB5-738E-4CC8-8D87-5B363B763CD3

P275

Q33618910-E492794B-84E6-4373-B788-356D4DA10651

P2860

Q33618910-01D621E3-1F6F-4BF3-AE56-EA1EE8A98BEC

Q33618910-07F40C33-8E50-4495-B5CF-E7B95C63A212

Q33618910-0C01A08F-0EB5-4BA2-869C-FA3D5E67DA31

Q33618910-15A5725A-76BC-42CC-9A32-71A8A06704A5

Q33618910-1931BA75-E0AE-4A69-BD63-6005AFAFECCB

Q33618910-1AF805F2-21C3-4AF9-9FC7-1DB27CCF3C4F

Q33618910-1BCF397B-D2B1-46B9-9D53-9F6BA1F8BC0A

Q33618910-212FC322-7F62-47F8-ABF8-282E6F08FF74

Q33618910-22BBE624-99E8-4EFE-976F-C22B50CD83B2

Q33618910-2450594C-CEA4-46DF-B22C-72AA14E2F3A8

P304

Q33618910-30B3932A-B4FC-4BF1-BE4F-8E24B829C703

P31

Q33618910-966E0BD7-CF80-49E3-B8A2-416B61F315F3

P356

Q33618910-ED52DDE8-43DB-429D-B481-547EDC550064

P407

Q33618910-A0CAC17F-A6F3-4B87-A174-6EE66D6F5F70

P433

Q33618910-9216050D-9E09-4B1C-BAD0-15A624D1D5C1

P478

Q33618910-A33D4145-7860-49EF-BCAE-B37C2207A692

P50

Q33618910-249FD6AB-E87F-4662-A66C-491F4D9D4356

Q33618910-4837E634-DD95-4FBD-BFE8-DB9C70D9E169

P577

Q33618910-4DD81690-A32A-4AA5-B92C-6AE36CA3DCF4

P698

Q33618910-C751B5AD-8A23-4D03-8414-0A9518C92AF5

P921

Q33618910-3FFCAABE-E6B9-4736-984F-B88DE77E2558

P932

Q33618910-BD7E5F2A-F310-413A-821F-C87C41A969FB

P356

ONCOTARGET.14409

P1433

P1476

"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitors

@en

P2093

Angela Listì

http://www.w3.org/2001/XMLSchema#string

Antonio Russo

http://www.w3.org/2001/XMLSchema#string

Francesc Passiglia

http://www.w3.org/2001/XMLSchema#string

Lorena Incorvaia

http://www.w3.org/2001/XMLSchema#string

Marcello Ciaccio

http://www.w3.org/2001/XMLSchema#string

Nadia Barraco

http://www.w3.org/2001/XMLSchema#string

Rossella Maragliano

http://www.w3.org/2001/XMLSchema#string

Sergio Rizzo

http://www.w3.org/2001/XMLSchema#string

Valentina Calò

http://www.w3.org/2001/XMLSchema#string

Viviana Bazan

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination

Successes and Challenges of PARP Inhibitors in Cancer Therapy

Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis

PARP inhibitors in the management of breast cancer: current data and future prospects

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

P304

23891-23904

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.14409

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Galvano

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28055979

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

P932

5410353

http://www.w3.org/2001/XMLSchema#string